抗VEGF抗体贝伐单抗在青光眼滤过性手术的应用  

The application of anti-VEGF antibody bevacizumab in glaucoma filtration surgery

作　　者：左磊[1] 许迅[2] 

机构地区：[1]上海市第一人民医院分院眼科,200081 [2]上海交通大学附属上海市第一人民医院眼科,200080

出　　处：《国际眼科纵览》2017年第5期323-327,共5页International Review of Ophthalmology

基　　金：上海市卫生和计划生育委员会科研课题重点项目（201640027）

摘　　要：新生血管化发生于青光眼滤过性手术的伤口愈合阶段,是对青光眼治疗的挑战.为提高手术成功率,近年来抗VEGF抗体贝伐单抗（bevacizumab,BVZ）应用于青光眼滤过性手术,如原发性开角型青光眼、色素性青光眼、剥脱性青光眼、慢性闭角型青光眼、新生血管性青光眼以及抗青光眼手术失败的再次青光眼滤过性手术.给药方式包括局部给药、结膜下注射、前房内注射、玻璃体内注射、联合给药等.Angiogenesis may pose a clinical challenge in glaucoma during the wound healing phase after glaucoma filtration surgery （GFS）.In recent years,anti-VEGF antibody bevacizumab （BVZ） has been used in GFS in order to improve the operation success rate safely,such as primary open angle glaucoma,pigmentary glaucoma,exfoliation glaucoma,chronic angle closure glaucoma,neovascular glaucoma,and the filtering surgery after failure of glaucoma surgery.The mode of application include topical,subconjunctival injection,intracameral injection,intravitreal injection,combination therapy,etc.

关 键 词：青光眼 青光眼滤过性手术 新生血管化 贝伐单抗 

分 类 号：R775[医药卫生—眼科]